NHS-IL2 combined with radiotherapy: preclinical rationale and phase Ib trial results in metastatic non-small cell lung cancer following first-line chemotherapy

BACKGROUND: NHS-IL2 (selectikine, EMD 521873, MSB0010445) consists of human NHS76 (antibody specific for necrotic DNA) fused to genetically modified human interleukin 2 (IL-2) and selectively activates the high-affinity IL-2 receptor. Based on an evolving investigational concept to prime the tumor m...

Descripción completa

Detalles Bibliográficos
Autores principales: van den Heuvel, Michel M, Verheij, Marcel, Boshuizen, Rogier, Belderbos, José, Dingemans, Anne-Marie C, De Ruysscher, Dirk, Laurent, Julien, Tighe, Robert, Haanen, John, Quaratino, Sonia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4320467/
https://www.ncbi.nlm.nih.gov/pubmed/25622640
http://dx.doi.org/10.1186/s12967-015-0397-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4320467/
https://www.ncbi.nlm.nih.gov/pubmed/25622640
http://dx.doi.org/10.1186/s12967-015-0397-0

Ejemplares similares